- Profound Medical Annual General Meeting of Shareholders Voting Results
- Profound Medical Receives U.S. FDA 510(k) Clearance for ‘Contouring Assistant’ AI Module that Enables Creation of an Automated TULSA Treatment Plan
- Profound Medical Announces First Quarter 2024 Financial Results and Issues Full-Year 2024 Revenue Guidance
- Growing Body of Clinical Evidence Points to the Potential of Profound Medical’s TULSA Procedure Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum
- Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow
- Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
- Profound Medical Announces Fourth Quarter and Full Year 2023 Financial Results
- Profound Medical to Participate in Barclays 26th Annual Global Healthcare Conference
- Profound Medical in Collaboration with Siemens Healthineers to Further Expand Physician and Patient Access to the TULSA Procedure
- Profound Medical to Release Fourth Quarter and Full Year 2023 Financial Results on March 7 – Conference Call to Follow
More ▼
Key statistics
As of last trade Profound Medical Corp (PRN:TOR) traded at 10.09, 5.65% above its 52-week low of 9.55, set on Jan 10, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.08 |
---|---|
High | 10.15 |
Low | 9.85 |
Bid | 10.03 |
Offer | 10.18 |
Previous close | 10.09 |
Average volume | 5.42k |
---|---|
Shares outstanding | 24.43m |
Free float | 22.30m |
P/E (TTM) | -- |
Market cap | 247.73m CAD |
EPS (TTM) | -1.76 CAD |
Data delayed at least 15 minutes, as of May 29 2024 20:59 BST.
More ▼